Anastrozole
Product Images NDC 66336-533

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 66336-533). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 66336-0533-xx (Ndc 66336 0533 Xx Accord)

Anastrozole 1 mg tablets packaging label from Dispensing Solutions, Inc., Santa Ana, CA. The label shows the drug name, strength, and dosage form with NDC 66336-0533. It includes directions to take one tablet orally once daily and warnings about potential side effects. The label also advises storing the product at 68°-77°F and keeping it out of children's reach.*

FDA Label Image

Chemical Structure For Anastrozole (D95c58fe 64cd 449a B76a 6989597c5dd0 01)

Chemical structure of Anastrozole, showing its molecular composition with a triazole ring attached to a phenyl ring substituted with nitrile and methyl groups.*

FDA Label Image

Figure 1 (D95c58fe 64cd 449a B76a 6989597c5dd0 02)

A Kaplan-Meier survival curve comparing disease-free survival over 96 months between two randomized treatment groups: anastrozole and tamoxifen. The y-axis represents the proportion alive and disease-free, while the x-axis shows disease-free survival in months. Patient numbers at risk are listed below the graph for both treatments at various time points.*

FDA Label Image

Figure 2 (D95c58fe 64cd 449a B76a 6989597c5dd0 03)

A Kaplan-Meier survival curve comparing disease-free survival over 84 months between patients treated with anastrozole and tamoxifen. The y-axis shows the proportion alive and disease-free, while the x-axis represents time in months. Numbers of patients at risk for each treatment group are listed below the x-axis.*

FDA Label Image

Figure3 (D95c58fe 64cd 449a B76a 6989597c5dd0 04)

A Kaplan-Meier survival curve chart comparing time to event in months for two randomized treatment groups: Anastrozole and Tamoxifen. The Y-axis shows the proportion event-free, ranging from 0.50 to 1.00. The chart includes a truncated vertical axis and displays numbers of patients at risk at various time points (0 to 120 months) for both groups.*

FDA Label Image

Figure4 (D95c58fe 64cd 449a B76a 6989597c5dd0 05)

A Kaplan-Meier survival curve comparing the proportion event-free over time (in months) for Anastrozole versus Tamoxifen treatments. The x-axis represents time to event in months up to 120 months, and the y-axis shows the proportion event-free ranging from 0.5 to 1. A table below the graph displays the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure5 (D95c58fe 64cd 449a B76a 6989597c5dd0 06)

A Kaplan-Meier survival plot showing proportion without progression over time in months. The graph compares two randomized treatment groups: Anastrozole (solid line) and Tamoxifen (dashed line), with patient numbers at risk listed below the x-axis.*

FDA Label Image

Figure6 (D95c58fe 64cd 449a B76a 6989597c5dd0 07)

A line graph comparing progression-free survival over time (in months) between two treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, while the y-axis shows the proportion of patients not progressed. Two lines, one for Anastrozole (solid) and one for Tamoxifen (dashed), depict the progression rates over a period extending to around 40 months. The number of patients at risk at various time points is displayed below the x-axis.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.